FDA Gives Rybrevant Faspro Accelerated Approval For Neck Cancer
The FDA cleared amivantamab plus hyaluronidase for head and neck cancer that came back after platinum chemotherapy and immunotherapy. It's the first new approval for these patients in ten years.
A ten-year wait for a new option ended November 5, and the approval rests on response data.
The FDA granted accelerated approval on November 5 to Rybrevant Faspro for head and neck cancer that returned after standard treatment.
The drug, amivantamab with hyaluronidase-lpuj, treats adults whose squamous cell carcinoma of the head and neck came back or spread after platinum chemotherapy and immunotherapy. Janssen Biotech makes it.
The approval breaks a long dry spell. These patients haven't had a newly approved therapy in ten years, and their cancer had already beaten the two standard drug classes.
The evidence comes from a trial of 102 patients. Tumors shrank in 42 percent of them, against 20 percent for the therapies that held approvals before this one.
Accelerated approval carries a condition. The FDA clears drugs on early evidence, here tumor response, and the maker still owes a confirmatory trial that shows patients live longer or feel better. The approval can come back off the label if that trial fails.
The label draws one clear line. The drug isn't indicated for HPV-associated oropharyngeal squamous cell carcinoma, a related cancer with a different driver.
For the patients inside the label, the practical change is simple. Oncologists now have an approved option to offer after the standard sequence runs out, instead of a trial referral or nothing.
The conversation.
Loading comments…
A little more perspective.
Reading is free. Verified members can comment and reply for $2 a month.